Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 
The feature you requested does not exist. However, we suggest the following feature:

Synairgen : Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis

08/05/2015 | 12:23am US/Eastern

SYDNEY and SOUTHAMPTON, England, Aug. 5, 2015 /PRNewswire/ -- Australian pharmaceutical company Pharmaxis Ltd (ASX: PXS) and UK biotechnology company Synairgen plc (LSE: SNG) today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).

Logo - http://photos.prnewswire.com/prnh/20150805/255537LOGO

IPF affects in the region of 100,000 people in the US. Current products are expected to produce global revenues in excess of $1.1 billion by 2017. The LOXL2 enzyme is being targeted because it is known to promote scar tissue which hardens and irreparably damages the lungs of IPF patients.  It is hoped that the inhibition of LOXL2 will slow the build-up of scar tissue and improve survival rates that are worse than for many cancers.

The LOXL2 inhibitor program comes from the same Pharmaxis chemistry platform as the SSAO inhibitor that was recently acquired by Boehringer Ingelheim. Under the terms of the agreement Synairgen will fund further activity of the program at Pharmaxis, use its BioBank and in vitro lung model platform, and collaborate with the IPF research team at the University of Southampton to complete pre-clinical and early clinical development. The IPF program will be managed by a joint steering committee through to the end of phase 1 or phase 2a clinical trials, at which time the collaboration will seek a license partner. Pharmaxis and Synairgen will share any licensing revenues in accordance with the ratio of total investment by the two companies at that time. The share of licensing revenues is expected to be approximately equal for a compound licensed for IPF after early clinical development. Pharmaxis will continue to develop compounds outside the collaboration for other indications where LOXL2 inhibitors have shown potential such as liver and kidney fibrosis, and metastatic cancer. The agreement does however allow for scenarios where the collaboration licenses its program for multiple indications.

Pharmaxis CEO Mr. Gary Phillips said, "We have continued to make good progress in our preclinical LOX inhibitor program and in particular on LOXL2 small molecule inhibitors to treat various diseases where fibrosis is a major problem. The significant interest among leading clinicians and pharmaceutical companies in the role of LOXL2 in a number of different diseases has highlighted the need for us to collaborate for selected indications in order to fully exploit the potential value of our intellectual property. Synairgen has a demonstrated excellence in respiratory drug development, having successfully licensed its inhaled IFN-beta Phase 2 program to AstraZeneca. We believe our collaboration with Synairgen will accelerate the development of a highly competitive once-a-day oral treatment for patients with IPF and enable Pharmaxis to develop LOXL2 inhibitors for other potential indications such as liver and kidney fibrosis, and cancer."

Synairgen CEO Richard Marsden said, "We are delighted to be collaborating with Pharmaxis in idiopathic pulmonary fibrosis, a severe and fatal lung disease. Pharmaxis has a proven competence in the discovery and development of novel molecules, making it an ideal partner. LOXL2 is a target which is of interest not only to our IPF clinical experts in Southampton but also to large pharmaceutical companies; in 2011 Gilead Sciences acquired Arresto Biosciences for $225 million for its Phase I LOXL2 targeting antibody simtuzumab and is currently conducting a large efficacy trial in IPF.

"Using existing financial resources from our fundraising in 2014, we will apply our BioBank platform of advanced human tissue models and understanding of respiratory biology to develop the LOXL2 inhibitor. We look forward to working closely with Pharmaxis and the world class academics at the University of Southampton to progress this opportunity into the clinic in patients with IPF."

CONTACT:

Pharmaxis Ltd
Felicity Moffatt, Pharmaxis Public Affairs
Tel: +61 418 677 701 or email felicity.moffatt@pharmaxis.com.au

Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: +44 (0) 23 8051 2800

Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Jessica Hodgson / Laura Thornton
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5701

© PR Newswire, source Africa Press Releases

React to this article
Latest news
Date Title
12:23a SYNAIRGEN : Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis
12:23aDJChina's Services Sector Posts Gains in July, Cushioning Factory Weakness
12:21a PJD PJ DEVELOPMENT BHD : Changes in Sub. S-hldr's Int. (29B) - OSK EQUITY HOLDINGS SDN BHD
12:21a PJD PJ DEVELOPMENT BHD : Changes in Sub. S-hldr's Int. (29B) - OSK HOLDINGS BERHAD
12:21a PJD PJ DEVELOPMENT BHD : Changes in Director's Interest (S135) - TAN SRI ONG LEONG HUAT @ WONG JOO HWA
12:21a PJD PJ DEVELOPMENT BHD : Changes in Sub. S-hldr's Int. (29B) - PUAN SRI KHOR CHAI MOI
12:21a PJD PJ DEVELOPMENT BHD : Changes in Sub. S-hldr's Int. (29B) - TAN SRI ONG LEONG HUAT @ WONG JOO HWA
12:21a BIT ISLE : Revision of the Consolidated Earnings Forecast for the Fiscal Year Ending July 31, 2015
12:21a CASH CONVERTERS : Update Banking Facilities
12:21a PJD PJ DEVELOPMENT BHD : Changes in Director's Interest (S135) - PUAN SRI KHOR CHAI MOI
Latest news
Advertisement
Hot News 
TRINET : INVESTOR ALERT: Investigation of TriNet Group Inc. Announced by The Law Offices of Howard G. Smith
FNB Corporation acquires Harrisburg-based Metro Bank in mega deal
MIDSTATES PETROLEUM : Announces Second Quarter 2015 Results
UNITED FIRE : profit jumps 41 percent in 2nd Quarter, premiums for new business remain strong
STONEMOR PARTNERS : announces scholarships for Catholic high school freshmen
Most Read News
08/04 DAIRY AUSTRALIA : DairyBase gets thumbs up from farmer
08/04 LA SHERIFF'S DEPARTMENT PAYS $5M TO SETTLE ACCIDENTAL SHOOTING DEATH, BUT REFUSES TO RELEASE COURT-ORDERED CORRECTIVE ACTION PLAN : Osborn Machler
08/04 COURSERA : Launches Global Skills Initiative to Link Up BNY Mellon, Cisco, Microsoft, Qualcomm, Splunk, and UBS with Top Universities to Create Online Courses in High Demand Fields
08/04 Zoloto Resources Begins Operations
08/04 CORIMON CA : MINUTES OF THE ANNUAL GENERAL SHARHOLDERS’ MEETING OF CORIMON, C.A. (July 31th, 2015)
Most recommended articles
12:15aDJMalaysia June Exports Unexpectedly Expand 5.0% on-Year
08/04 JPMorgan-linked China joint venture gets approval to invest overseas
08/04 EUR/GBP TECHNICAL ANALYSIS : Support Sub-0.70 Under Fire
08/04 USD/CAD TECHNICAL ANALYSIS : Prices Rise to 11-Year High
08/04 AUD/USD TECHNICAL ANALYSIS : Aussie Rallies Most in 2 Months